Express Mail Label No.
EL844512075US
Date of Deposit: **06-19-01**

ATTORNEY'S DOCKET NO. G0694/7002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Richard S. Blumberg
Serial No:	Unknown
Filed:	Herewith
For:	T Cell Inhibitory Receptor Compositions and Uses Thereof

Box Patent Application
Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the fees, please amend the application as follows.

In the Claims

Please cancel claims 1-9, 19-39 and 49-56 without prejudice.

Please amend the claims as follows:

11.(amended) The method of claim 10, wherein the agent is an antibody or a fragment thereof that increases cross-linking of biliary glycoprotein.

41.(amended) The method of claim 40, wherein the agent is an antibody or a fragment thereof that increases cross-linking of biliary glycoprotein.

Please add the following new claims:

57.(new) The method of claim 11, wherein the antibody is a chimeric antibody or a humanized antibody.

58.(new) The method of claim 11, wherein the antibody is a CD66a monoclonal antibody.

59.(new) The method of claim 15, wherein the fragment of biliary glycoprotein is selected from the group consisting of the N-domain of CD66a, NA1B1 domains of CD66a, and the NA1B1A2 domains of CD66a.

60.(new) The method of claim 41, wherein the antibody is a chimeric antibody or a humanized antibody.

61.(new) The method of claim 41, wherein the antibody is a CD66a monoclonal antibody.

62.(new) The method of claim 45, wherein the fragment of biliary glycoprotein is selected from the group consisting of the N-domain of CD66a, NA1B1 domains of CD66a, and the NA1B1A2 domains of CD66a.

Remarks

Applicant has amended claims 11 and 41 to include antibody fragments. Support for this amendment is found in the specification as filed, for example, at page 11. Applicant has added new claims 57-62 to specify the antibodies and fragments of biliary glycoprotein in the claimed methods. Claims 57, 58, 60 and 61 are supported in the specification at pages 10 to 12. Claims 59 and 62 are supported in the application as filed, for example in page 28, lines 2-12. No new matter has been added by these amendments.

Respectfully submitted,

John R. Van Amsterdam
Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
(617) 720-3500

Docket No.: G0694/7002
Dated: June 19, 2001
Xndd

541648_1.DOC

Amended Claims

11.(amended) The method of claim 10, wherein the agent is an antibody or a fragment thereof that increases cross-linking of biliary glycoprotein.

41.(amended) The method of claim 40, wherein the agent is an antibody or a fragment thereof that increases cross-linking of biliary glycoprotein.

New Claims

57.(new) The method of claim 11, wherein the antibody is a chimeric antibody or a humanized antibody.

58.(new) The method of claim 11, wherein the antibody is a CD66a monoclonal antibody.

59.(new) The method of claim 15, wherein the fragment of biliary glycoprotein is selected from the group consisting of the N-domain of CD66a, NA1B1 domains of CD66a, and the NA1B1A2 domains of CD66a.

60.(new) The method of claim 41, wherein the antibody is a chimeric antibody or a humanized antibody.

61.(new) The method of claim 41, wherein the antibody is a CD66a monoclonal antibody.

62.(new) The method of claim 45, wherein the fragment of biliary glycoprotein is selected from the group consisting of the N-domain of CD66a, NA1B1 domains of CD66a, and the NA1B1A2 domains of CD66a.